These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 4006373)

  • 21. A pharmacokinetic study of roxatidine acetate in chronic renal failure.
    Lameire N; Rosenkranz B; Maass L; Brockmeier D
    Drugs; 1988; 35 Suppl 3():48-52. PubMed ID: 2905249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacokinetics of cefotaxime and metabolites in uremic patients (author's transl)].
    Fillastre JP; Ings RM; Leroy A; Godin M; Humbert G
    Nephrologie; 1982; 3(1):12-8. PubMed ID: 6283411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relation between type of renal disease and renal drug clearance in children.
    Paap CM; Nahata MC
    Eur J Clin Pharmacol; 1993; 44(2):195-7. PubMed ID: 8453966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of cefotaxime and desacetyl-cefotaxime in cirrhosis of the liver.
    Höffken G; Lode H; Koeppe P; Ruhnke M; Borner K
    Chemotherapy; 1984; 30(1):7-17. PubMed ID: 6319092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single-dose ceftriaxone kinetics in the newborn.
    Schaad UB; Hayton WL; Stoeckel K
    Clin Pharmacol Ther; 1985 May; 37(5):522-8. PubMed ID: 3987175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disposition of misoprostol and its active metabolite in patients with normal and impaired renal function.
    Foote EF; Lee DR; Karim A; Keane WF; Halstenson CE
    J Clin Pharmacol; 1995 Apr; 35(4):384-9. PubMed ID: 7650228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isepamicin disposition in subjects with various degrees of renal function.
    Halstenson CE; Kelloway JS; Affrime MB; Lin CC; Teal MA; Shapiro BE; Awni WM
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2382-7. PubMed ID: 1804011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of cefmenoxime in patients with impaired renal function and in those undergoing hemodialysis.
    Konishi K
    Antimicrob Agents Chemother; 1986 Dec; 30(6):901-5. PubMed ID: 3468882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ceforanide kinetics in renal insufficiency.
    Hawkins SS; Alford RH; Stone WJ; Smyth RD; Pfeffer M
    Clin Pharmacol Ther; 1981 Oct; 30(4):468-74. PubMed ID: 7285481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment.
    Patel IH; Sugihara JG; Weinfeld RE; Wong EG; Siemsen AW; Berman SJ
    Antimicrob Agents Chemother; 1984 Apr; 25(4):438-42. PubMed ID: 6329080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of the combination of ticarcillin with clavulanic acid in renal insufficiency.
    Dalet F; Amado E; Cabrera E; Donate T; del Rio G
    J Antimicrob Chemother; 1986 May; 17 Suppl C():57-64. PubMed ID: 3722047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disposition of minoxidil in patients with various degrees of renal function.
    Halstenson CE; Opsahl JA; Wright CE; Fleishaker JC; Andreadis NA; Sobieraj J; Matzke GR
    J Clin Pharmacol; 1989 Sep; 29(9):798-802. PubMed ID: 2808745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of cefotaxime in the postpartum patient.
    Gonik B; Cotton DB; Feldman S; Cleary TG; Pickering LK
    Am J Perinatol; 1985 Apr; 2(2):114-7. PubMed ID: 4096751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of pregabalin in subjects with various degrees of renal function.
    Randinitis EJ; Posvar EL; Alvey CW; Sedman AJ; Cook JA; Bockbrader HN
    J Clin Pharmacol; 2003 Mar; 43(3):277-83. PubMed ID: 12638396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kinetic interactions between azlocillin, cefotaxime, and cefotaxime metabolites in normal and impaired renal function.
    Kampf D; Borner K; Möller M; Kessel M
    Clin Pharmacol Ther; 1984 Feb; 35(2):214-20. PubMed ID: 6319069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Famotidine disposition in children and adolescents with chronic renal insufficiency.
    Maples HD; James LP; Stowe CD; Jones DP; Hak EB; Blumer JL; Vogt B; Wilson JT; Kearns GL; Wells TG;
    J Clin Pharmacol; 2003 Jan; 43(1):7-14. PubMed ID: 12520622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects.
    Shah A; Lettieri J; Blum R; Millikin S; Sica D; Heller AH
    J Antimicrob Chemother; 1996 Jul; 38(1):103-16. PubMed ID: 8858462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cefmenoxime pharmacokinetics in healthy volunteers and subjects with renal insufficiency and on hemodialysis.
    Gambertoglio JG; Alexander DP; Barriere SL
    Antimicrob Agents Chemother; 1984 Dec; 26(6):845-9. PubMed ID: 6098220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination.
    Ings RM; Reeves DS; White LO; Bax RP; Bywater MJ; Holt HA
    J Pharmacokinet Biopharm; 1985 Apr; 13(2):121-42. PubMed ID: 4057054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction.
    Wise R; Wright N
    Infection; 1985; 13 Suppl 1():S145-50. PubMed ID: 4055047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.